Reuters logo
BRIEF-Repros requests meeting with FDA to discuss phase 3 requirements for proellex in the treatment of symptomatic uterine fibroids
December 12, 2016 / 9:20 PM / 10 months ago

BRIEF-Repros requests meeting with FDA to discuss phase 3 requirements for proellex in the treatment of symptomatic uterine fibroids

Dec 12 (Reuters) - Repros Therapeutics Inc :

* Says company anticipates a meeting will be scheduled during first half of 2017

* Repros Therapeutics Inc - objective of meeting with fda is primarily to agree on phase 3 clinical program

* Repros requests meeting with FDA to discuss phase 3 requirements for proellex in the treatment of symptomatic uterine fibroids Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below